Oculis Holding AG (OCS) is experiencing a notable rise in its stock price following the announcement of positive phase 2 trial results for its lead neuroprotective therapy, OCS-05. The trial, conducted in partnership with Accure Therapeutics, met its primary safety endpoint and key secondary efficacy endpoints without any serious adverse events. This success underscores the potential of OCS-05 in treating acute optic neuritis, a neurodegenerative disorder, and highlights the promising collaboration between Oculis and Accure. The positive trial outcomes have bolstered investor confidence in Oculis's ability to deliver transformative therapies in the field of ophthalmic and neurological conditions.
Oculis Holding AG's stock is currently trading at $20.47, reflecting a 9.47% increase from its previous close of $18.70.